Global Xerostomia Therapeutics Market 2019-2023
About this market
The most common disease that causes xerostomia is an inflammatory autoimmune disease. Additionally, central nervous system- related diseases including stress, depression, and anxiety can also lead to xerostomia. Moreover, trauma to the head and neck area can alter the nerve stimuli to the mouth and impair the function to the salivary glands. Therefore, the rising incidence of the health conditions or diseases that are high- risk factors for xerostomia is expected to continue to support the growth of the global xerostomia therapeutics market during the forecast period. According to our industry experts, the xerostomia therapeutics market to grow at a CAGR of over 3% during the forecast period.
Growing geriatric population
The increasing number of people with xerostomia is directly related to the growing geriatric population. The number of old people worldwide has been growing significantly over the years. This expected to contribute significantly to the market as this high growth in the older population helps to drive the sales of various therapeutics markets during our forecast period.
Product recalls and tedious drug approval process
Regulatory bodies have framed stringent regulations to grant marketing approval for therapeutics that are being newly developed for the treatment of xerostomia. Many applications rejected either due to the inadequate performance of the drug or because the information on the drug, which is submitted is unsatisfactory. Such stringent government regulations can lead to a delay in drug in drug approval which in turn hampers the growth of the market.
For the detailed list of factors that will drive and challenge the growth of the xerostomia therapeutics market during the 2019-2023, view our report.
The xerostomia therapeutics market is fragmented due to presence of many vendors in the market. The pharmaceutical companies are forming strategic collaborations which will enhance the R&D activities for new drugs for the management xerostomia. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Technavio Announces the Publication of its Research Report – Global Xerostomia Therapeutics Market 2019-2023
Technavio recognizes the following companies as the key players in the global xerostomia therapeutics market: Colgate-Palmolive, DAIICHI SANKYO, Eisai, GlaxoSmithKline, ORAHEALTH.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is the strategic alliances are expected to support the growth of the global xerostomia therapeutics market during our forecast period.”
According to the report, one of the major drivers for this market is the rising incidence of the health conditions or dieases that are high- risk factors for xerostomia is expected to continue to support the growth of the market during our forecast period.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook